Verastem Inc (VSTM)
9.31
-0.30
(-3.12%)
USD |
NASDAQ |
Apr 24, 16:00
9.301
-0.01
(-0.10%)
After-Hours: 20:00
Verastem Enterprise Value: 138.57M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 24, 2024 | 138.57M |
April 23, 2024 | 146.16M |
April 22, 2024 | 149.45M |
April 19, 2024 | 151.98M |
April 18, 2024 | 161.85M |
April 17, 2024 | 177.29M |
April 16, 2024 | 179.57M |
April 15, 2024 | 183.11M |
April 12, 2024 | 188.93M |
April 11, 2024 | 201.84M |
April 10, 2024 | 188.93M |
April 09, 2024 | 200.07M |
April 08, 2024 | 203.11M |
April 05, 2024 | 192.48M |
April 04, 2024 | 189.69M |
April 03, 2024 | 206.14M |
April 02, 2024 | 194.50M |
April 01, 2024 | 199.82M |
March 28, 2024 | 201.59M |
March 27, 2024 | 202.09M |
March 26, 2024 | 196.27M |
March 25, 2024 | 194.61M |
March 22, 2024 | 207.51M |
March 21, 2024 | 204.73M |
March 20, 2024 | 201.19M |
Date | Value |
---|---|
March 19, 2024 | 189.05M |
March 18, 2024 | 171.60M |
March 15, 2024 | 181.21M |
March 14, 2024 | 168.56M |
March 13, 2024 | 174.63M |
March 12, 2024 | 177.01M |
March 11, 2024 | 192.17M |
March 08, 2024 | 195.46M |
March 07, 2024 | 201.02M |
March 06, 2024 | 223.78M |
March 05, 2024 | 216.44M |
March 04, 2024 | 223.78M |
March 01, 2024 | 232.12M |
February 29, 2024 | 217.96M |
February 28, 2024 | 226.81M |
February 27, 2024 | 234.65M |
February 26, 2024 | 233.89M |
February 23, 2024 | 224.03M |
February 22, 2024 | 207.34M |
February 21, 2024 | 214.67M |
February 20, 2024 | 223.27M |
February 16, 2024 | 217.71M |
February 15, 2024 | 199.76M |
February 14, 2024 | 202.79M |
February 13, 2024 | 199.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-17.29M
Minimum
Oct 20 2022
732.38M
Maximum
Jun 21 2021
182.82M
Average
151.98M
Median
Enterprise Value Benchmarks
Johnson & Johnson | 364.33B |
Geron Corp | 1.703B |
Altimmune Inc | 304.12M |
Oragenics Inc | 3.306M |
Actinium Pharmaceuticals Inc | 130.86M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -27.37M |
Total Expenses (Quarterly) | 31.14M |
EPS Diluted (Quarterly) | -1.03 |
Earnings Yield | -44.15% |
Normalized Earnings Yield | -52.85 |